Celyad Oncology SA: Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
By Denny Jacob BrainStorm Cell Therapeutics shares rose 7.2% to 35 cents following a submitted special protocol assessment request to the Food and Drug.
Bluebird Bio stock plummeted after the biotech priced a stock offering at $1.50 a share. A landmark FDA approval for its sickle cell disease gene therapy has.
The Food and Drug Administration on Friday approved two gene therapies to treat patients with sickle cell disease. The new treatments, one developed by.
Crispr Therapeutics and Vertex Pharmaceuticals got U.S. regulatory approval for a sickle-cell disease treatment based on the gene-editing technology Crispr.